BioPharmaSpec Opens a New Lab in Pennsylvania to Provide Characterization Services to the US Biopharmaceutical Market
June 9, 2015 | By Business Wire News
PHILADELPHIA
BioPharmaSpec Inc. (“BioPharmaSpec”), a leading analytical research laboratory (CRO) providing a full range of characterization services for the pharmaceutical and biotechnology industries, today announced the opening of a new lab facility in Malvern, Pennsylvania, in the greater Philadelphia area.
“The Eastern seaboard of the United States, including the tri-state area of Pennsylvania, New Jersey and Delaware, is home to a good proportion of the U.S. pharmaceutical industry. The demand for our characterization services from North and South America has also been strong, due to the technical biochemical and instrumentation expertise we have built up over 40 years in analytical areas such as De Novo Protein Sequencing, Peptide Mapping, Disulfide Bridge and Carbohydrate Analysis. We look forward to using this expertise in our new laboratory to assist our American clients more readily with a full range of cost-effective services” commented BioPharmaSpec Founder and President Professor Howard R. Morris. “Our new facility in Malvern is a fully-equipped, modern laboratory, capable of a broad range of biopharmaceutical characterization services, with the quick turnaround for our North and South American client base that would only be possible with a domestic facility.”
Prof. Morris added, “We encourage all interested parties to visit us at BIO. We would be delighted to discuss your development projects and explore how we can help fulfill your characterization needs.”
BioPharmaSpec will be on-site at the BIO International Convention, Booth # 359.
For more information, please visit the company’s BIO page.
Key Contact info for BioPharmaSpec’s new lab:
BioPharmaSpec Inc.
363 Phoenixville Pike
Malvern, PA 19355
Tel: 610-640-5866
services.usa@biopharmaspec.com
About BioPharmaSpec
BioPharmaSpec is a contract research organization (CRO), founded by Professor Howard R. Morris and Dr. Andrew Reason, specializing in the structural and physico-chemical characterization and testing of Biopharmaceutical Products. Our experience includes structural characterization and physico-chemical analysis of recombinant biopharmaceuticals including biosimilars and biobetters, monoclonal antibodies, Antibody Drug Conjugates (ADCs) and blood circulating hormones.
Using state-of-the-art Chromatographic and Mass Spectrometric instrumentation together with classical biochemical instrumentation, including Gas Phase Sequencers and capillary IsoElectric Focussing, BioPharmaSpec applies expertise built up over 40 years of pioneering academic and industrial research, to assist Clients in a number of analytical areas including De Novo Protein Sequencing, Peptide and Glycopeptide Mapping, Disulfide Bridge Assignment, Carbohydrate Analysis and Structure Elucidation.
For more information, visit www.BioPharmaSpec.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150609005865/en/
BioPharmaSpec Inc.
Mark Di Ioia, 610-640-5866
Business Development
m.di-ioia@biopharmaspec.com
services.usa@biopharmaspec.com
or
Media:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com
